ERBB2 and lung carcinoma: Future directions include combining TIL ACT with HD IL-2 and chemotherapy (phase II, NCT01174121), combining anti-carcinoembryonic antigen (CEA)-specific autologous T cells with IL-2 in CEA+ metastatic gastric, colorectal, and lung cancers (phase II, NCT01723306), combining NK cell ACT with anti-HER2/neu biologic therapy in HER2R+ gastric cancers (phase I/II, NCT02030561), and assessing DC and CIK cell ACT in combination with chemotherapy for recurrent or metastatic gastric or esophagogastric junctional adenocarcinomas (phase I/II, NCT01783951).